Malignant Digestive System Neoplasm

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

In this phase III, randomized, open-label trial, 377 patients with wild-type KRAS exon two were randomized 1:1 to receive panitumumab 6 mg/kg IV on day 1 of each 14-day cycle plus BSC or BSC alone. Th… (full text at CIViC)

PMID 27736842 · Kim et al., 2016 · Open in CIViC

NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.

PMID 21900593 · Yonesaka et al., 2011 · Open in CIViC

Two patients with pancreatic adenocarcinoma harboring NRG1 gene fusions were treated with afatinib. Both of them showed a tumor response.

PMID 31068372 · Jones et al., 2019 · Open in CIViC

Reduced NT5C expression by shRNA significantly increased fluorouracil sensitivity in all three tested colorectal cancer cell lines, with IC50 decreases of approximately 3- to 6-fold.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.

PMID 25520391 · Cushman et al., 2015 · Open in CIViC

A 71-year-old male with esophageal carcinoma harboring NTRK1 amplification, based on FoundationOne CDx profiling test, was treated with larotrectinib. Treatment with larotrectinib led to a shrinkage o… (full text at CIViC)

PMID 32323889 · Hempel et al., 2020 · Open in CIViC

In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mito… (full text at CIViC)

PMID 21135251 · Villarroel et al., 2011 · Open in CIViC

For this single-arm phase II trial patients with locally advanced or metastatic pancreatic cancer (neuroendocrine excluded); and had a confirmed pathogenic or likely pathogenic germline (g) or somatic… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

A patient with pancreatic ductal adenocarcinoma (PDAC) and a somatic PALB2 mutation (NM_024675.4: c.3350+1G>T) experienced disease progression after 10 cycles of FOFIRINOX and 2 cycles of gemcitabine.… (full text at CIViC)

PMID 36119518 · Kachmazov et al., 2022 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

The frequent deletion of PBLD in HCC tissues is an independent predictor of poor prognosis for patients with HCC. Elevated PBLD expression has been show to reduce the growth and spread of HCC.

PMID 26594798 · Li et al., 2016 · Open in CIViC

In biliary tract cancer (BTC) models with PBRM1 loss-of-function (EGI1 and CCC5), sensitivity to PARP inhibitors increased significantly, with lower IC50 values for niraparib (2.25 µM vs 6.62 µM, p = … (full text at CIViC)

PMID 37400502 · Zimmer et al., 2023 · Open in CIViC

In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification.

PMID 22292935 · Shi et al., 2012 · Open in CIViC

474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 resp… (full text at CIViC)

PMID 24608574 · Fritsch et al., 2014 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild-type PIK3CA mutation (P = 0.035).

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

In a study of 413 patients with colorectal cancer who were taking aspirin since diagnosis, the frequency of PIK3CA mutations was 17% (70/413). In 530 patients with colorectal cancer not using aspirin,… (full text at CIViC)

PMID 23094721 · Liao et al., 2012 · Open in CIViC

In a panel of 20 gastric cancer cell lines, the line that showed greatest sensitivity to AZD5363 in MTS cell proliferation assay contained both PIK3CA E542K and PTEN Loss.

PMID 24088382 · Li et al., 2013 · Open in CIViC

In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA … (full text at CIViC)

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

In colorectal cancer patients treated with salvage cetuximab therapy in combination with chemotherapy, PIK3CA mutations were associated with reduced progression-free survival (2.5mo vs. 3.9mo, HR:2.1,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a study of 413 patients with colorectal cancer who were taking aspirin since diagnosis, the frequency of PIK3CA mutations was 17% (70/413). In 530 patients with colorectal cancer not using aspirin,… (full text at CIViC)

PMID 23094721 · Liao et al., 2012 · Open in CIViC

Phosphatidylinositol 3-kinase (PIK3CA) is composed of an 85kDa regulatory subunit and a 110kDa (p110alpha) catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which u… (full text at CIViC)

PMID 9742087 · Klippel et al., 1998 · Open in CIViC

This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA exon 10 and 21 mu… (full text at CIViC)

PMID 19903786 · He et al., 2009 · Open in CIViC

Phosphatidylinositol 3-kinase (PIK3CA) is composed of an 85kDa regulatory subunit and a 110kDa (p110alpha) catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which u… (full text at CIViC)

PMID 9742087 · Klippel et al., 1998 · Open in CIViC

Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E545Q (exon 10), were wildtype for NRAS, B… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA … (full text at CIViC)

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

In colorectal cancer patients treated with salvage cetuximab therapy in combination with chemotherapy, PIK3CA mutations were associated with reduced progression-free survival (2.5mo vs. 3.9mo, HR:2.1,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E81K, were wildtype for NRAS, BRAF and PIK… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. … (full text at CIViC)

PMID 22357840 · Liao et al., 2012 · Open in CIViC

In chemotherapy-refractory patients with metastatic colorectal cancer and KRAS wt tumors, Exon 10 PIK3CA mutations (listed as Exon 9 in the source) had no significant impact on response rate (6/21 [28… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. … (full text at CIViC)

PMID 22357840 · Liao et al., 2012 · Open in CIViC

Chemotherapy-refractory patients with metastatic colorectal cancer harboring wildtype KRAS and Exon 21 (listed as exon 20 in the source) PIK3CA mutations had lower response rates (0/9 vs 121/329; OR: … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a prospective study involving 1,170 colorectal cancer patients confirmed by histology. PIK3CA mutations were found in 16% (189/1170) of cased via pyrosequencing of FFPE samples, of these 58% … (full text at CIViC)

PMID 22357840 · Liao et al., 2012 · Open in CIViC

In a randomized double-blind placebo-controlled biomarker-selected adjuvant study (ALASCCA, NCT02647099; colorectal carcinoma; n = 626; group A: PIK3CA exon 9/20, n = 314), aspirin 160 mg daily (group… (full text at CIViC)

PMID 40961426 · Martling et al., 2025 · Open in CIViC